1. Mechanism of RNA circHIPK3 Involved in Resistance of Lung Cancer Cells to Gefitinib
- Author
-
Yi Zhao, Caiming Zhang, Haibo Tang, Xiaomin Wu, and Qiugan Qi
- Subjects
Lung Neoplasms ,Article Subject ,General Immunology and Microbiology ,Gefitinib ,RNA, Circular ,General Medicine ,General Biochemistry, Genetics and Molecular Biology ,respiratory tract diseases ,MicroRNAs ,Cell Line, Tumor ,Lymphatic Metastasis ,Humans ,Lung ,Cell Proliferation - Abstract
To study the mechanism of circular ribonucleic acid (RNA) circHIPK3 involved in the resistance of lung cancer cells to gefitinib, 110 patients with lung cancer were recruited as the research objects, and the tumor tissue and para-cancerous tissue of each patient’s surgical specimens were collected and paraffinized to detect the expression of circHIPK3 in different tissues. Gefitinib drug-resistant cell line of lung cancer was constructed with gefitinib to detect cell apoptosis under different conditions. As a result, the relative expression of circHIPK3 in patients with tumor diameter no less than 3 cm was dramatically inferior to that in patients with tumor diameter less than 3 cm ( P < 0.05 ). The relative expression of circHIPK3 in patients with TNM stage II/III was dramatically inferior to that in patients with tumor, node, and metastasis (TNM) stage I ( P < 0.05 ). Expression of circHIPK3 in patients with lymph node metastasis was dramatically inferior to that in patients without lymph node metastasis ( P < 0.05 ). Of the lung cancer tissues of patients with different TNM stages, only six patients had high expression, and the remaining 104 patients had low expression. Moreover, electrophoresis revealed that circHIPK3 can only be amplified in cDNA, but not in gDNA. Gefitinib-mediated apoptosis rate of lung cancer drug-resistant cell lines decreased notably. In summary, the circular RNA circHIPK3 may have a notably low expression in lung cancer tissues, whose low expression had a certain enhancement effect on the drug resistance of lung adenocarcinoma cells to gefitinib.
- Published
- 2022